Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Polish Myeloma Consortium
Sponsor

Polish Myeloma Consortium

Poland Ul. Augustyna Szamarzewskiego 84, 60-569 Poznan, Poland

About the sponsor

The Polish Myeloma Consortium supports clinical research in multiple myeloma with a focus on treatment strategies for patients with biochemical relapse and newly diagnosed disease. Its research activity includes evaluation of anti-CD38 therapy and combination regimens used in disease control.

  • Daratumumab-based therapy
  • Relapsed myeloma
  • Newly diagnosed multiple myeloma
  • Combination treatment regimens

Clinical interest extends to outcomes linked with disease progression, response maintenance, and prevention of symptomatic relapse in plasma cell dyscrasias.

About Specializations

Polish Myeloma Consortium runs clinical trials in conditions such as Plasma cell myeloma, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Plasma cell myeloma

Not yet recruiting

Teclistamab drug combination versus daratumumab and lenalidomide in MRD‑positive multiple myeloma patients after stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

Plasma cell myeloma

Not yet recruiting

Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Polish Myeloma Consortium

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Carfilzomib, and Dexamethasone with Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Polish Myeloma Consortium

Plasma cell myeloma

Not recruiting

Study on Daratumumab for Multiple Myeloma Patients with Minimal Residual Disease Reappearance or Biochemical Relapse

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.